Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Cited by (675)

Items 301–400 of 675

1. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective
   Angela Holly Villamagna, Sara J Gore, James S. Lewis, J. Stone Doggett · 2020 · Frontiers in Medicine
2. Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19)
   Hatem A Hejaz · 2020 · Avicenna Journal of Medicine
3. Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review
   Abdulbaset Al-Romaima, Yinan Liao, Jie Feng, Xihui Qin, Guiming Qin · 2020 · Journal of Thoracic Disease
4. Methods of Synthesis of Remdesivir, Favipiravir, Hydroxychloroquine, and Chloroquine: Four Small Molecules Repurposed for Clinical Trials during the Covid-19 Pandemic
   Nader R. Albujuq · 2020 · Synthesis
5. Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs
   M. Idda, D. Soru, M. Floris · 2020 · Frontiers in Public Health
6. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
   Sally El Kantar, Bilal Nehmeh, Philippe Saad, Gabie Mitri, Celine Estephan, Mohamad A. Mroueh, Elias Akoury, Robin I. Taleb · 2020 · Drug Discovery Today
7. Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena
   Arghadip Samaddar, Malika Grover, Vijaya Lakshmi Nag · 2020 · Frontiers in Pharmacology
8. Critical Care Management of Patients with COVID-19: Early Experience in Thailand
   R. Ratanarat, C. Sivakorn, T. Viarasilpa · 2020 · American Journal of Tropical Medicine and Hygiene
9. Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)
   T. Siripongboonsitti, Marisa Muadchimkaew, K. Tawinprai · 2023 · Scientific Reports
10. Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
    Kritika Srinivasan Rajsri, Mana Rao · 2021 · Therapeutic Advances in Infectious Disease
11. EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19)
    L. Balykova, V. Pavelkina, N. V. Shmyreva · 2020 · Pharmacy and Pharmacology
12. Recent perspectives and awareness on transmission, clinical manifestation, quarantine measures, prevention and treatment of COVID-19 among people living in Malaysia in 2020
    Alabed Ali A. Alabed, Asita Elengoe, Elan Selvi Anandan, Abdullah Y. Al‐Mahdi · 2020 · Journal of Public Health
13. Is there any potential management against COVID-19? A systematic review and meta-analysis
    Haleh Talaie, Sayed Masoud Hosseini, Maryam Nazari, Yadolah Fakhri, Atieh Mousavizadeh, Hossein Vatanpour, Ali Firoozfar · 2020 · DARU Journal of Pharmaceutical Sciences
14. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID‐19) and the rationale for their utilization: A review
    Richard Giovane, Shadi Rezai, Ellen Cleland, Cassandra E. Henderson · 2020 · Reviews in Medical Virology
15. Revealing Anti-viral Potential of Bio-active Therapeutics Targeting SARS-CoV2- polymerase (RdRp) in Combating COVID-19: Molecular Investigation on Indian Traditional Medicines
    D. Sivaraman, P. Pradeep · 2020
16. Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand
    Pinyo Rattanaumpawan, Supunnee Jirajariyavej, Kanokorn Lerdlamyong, Nattawan Palavutitotai, Jatuporn Saiyarin · 2022 · Antibiotics
17. Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus
    Josidel Conceição Oliver, Evandro Neves Silva, Letícia Martins Soares, Gislaine Cristina Scodeler, Ana de Souza Santos, Patrícia Paiva Corsetti, Carlos Roberto Prudêncio, Leonardo Augusto de Almeida · 2022 · Therapeutic Advances in Vaccines and Immunotherapy
18. Strategies for drug repurposing against coronavirus targets
    Poppy O. Smith, Peiqin Jin, Khondaker Miraz Rahman · 2021 · Current Research in Pharmacology and Drug Discovery
19. Clinical features and mechanistic insights into drug repurposing for combating COVID-19
    Purva Asrani, Keshav Tiwari, Mathew Suji Eapen, Kielan Darcy McAlinden, Greg Haug, Matt D. Johansen, Philip M. Hansbro, Katie L. Flanagan, Md. Imtaiyaz Hassan, Sukhwinder Singh Sohal · 2021 · The International Journal of Biochemistry & Cell Biology
20. Potential drug development and therapeutic approaches for clinical intervention in COVID-19
    Jayanta Dowarah, Brilliant N. Marak, Umesh C. S. Yadav, Ved Prakash Singh · 2021 · Bioorganic Chemistry
21. Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection
    K. Kasyanenko, O. V. Maltsev, K. Kozlov · 2021 · Antibiotics and Chemotherapy
22. COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review
    C. T. Dhanya Raj, Surabhi Kandaswamy, Ravi Chandra Sekhara Reddy Danduga, Raju Rajasabapathy, Rathinam Arthur James · 2021 · Archives of Microbiology
23. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study
    A. Uçan, P. Çerçi, Serdar Efe · 2021 · Virology Journal
24. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding
    Marcelo Borges Cavalcante, Candice Torres de Melo Bezerra Cavalcante, Ana Catherine Sampaio Braga, Dennyse Araújo Andrade, Mariana Albuquerque Montenegro, Paula Andrade Neiva Santos, Paula Vitória Pereira Motoyama, Marcelo Gondim Rocha, L.A. Dib, Edward Araujo Júnior · 2021 · Geburtshilfe und Frauenheilkunde
25. What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results
    Vanessa Aparecida Marcolino, Tatiana Colombo Pimentel, Carlos Eduardo Barão · 2020 · European Journal of Pharmacology
26. The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications
    Sohil Ahmed Khan, Michael R. Gionfriddo, Nicolas W. Cortes-Penfield, Girish Thunga, Muhammed Rashid · 2020 · Expert Opinion on Pharmacotherapy
27. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection
    Maryam Amini Pouya, Seyyedeh Maryam Afshani, Armin Salek Maghsoudi, Shokoufeh Hassani, Kayvan Mirnia · 2020 · DARU Journal of Pharmaceutical Sciences
28. Electrochemical sensor for simultaneous determination of antiviral favipiravir drug, paracetamol and vitamin C based on host–guest inclusion complex of β-CD/CNTs nanocomposite
    Yousef M. Ahmed, Mahmoud A Eldin, A. Galal · 2023 · Scientific Reports
29. Favipiravir—Tautomeric and Complexation Properties in Solution
    V. Deneva, S. Slavova, Alina Kumanova · 2022 · Pharmaceuticals
30. Investigational antiviral drugs for the treatment of COVID-19 patients
    Samineh Beheshtirouy, Elnaz Khani, Sajad Khiali, Taher Entezari‐Maleki · 2022 · Archives of Virology
31. DrugDevCovid19: An Atlas of Anti-COVID-19 Compounds Derived by Computer-Aided Drug Design
    Yang Liu, Jianhong Gan, Rongqi Wang, Xiaocong Yang, Zhi‐Xiong Jim Xiao, Yang Cao · 2022 · Molecules
32. Modalities and Mechanisms of Treatment for Coronavirus Disease 2019
    Zhihong Zuo, Ting Wu, Liangyu Pan, Chenzhe Zuo, Yingchuo Hu, Xuan Luo, Li-Ping Jiang, Zanxian Xia, Xiao-Juan Xiao, Jing Liu et al. · 2021 · Frontiers in Pharmacology
33. Reporting and design of randomized controlled trials for COVID-19: A systematic review
    Alison Dillman, Jay Park, Michael J. Zoratti, Noor-E Zannat, Zelyn Lee, Louis Dron, Grace G. Hsu, Gerald Smith, Sahand Khakabimamaghani, Ofir Harari et al. · 2020 · Contemporary Clinical Trials
34. Repurposing current therapeutic regimens against SARS-CoV-2 (Review)
    Sofia Marina Konstantinidou, Ioannis P. Papanastasiou · 2020 · Experimental and Therapeutic Medicine
35. Signal amplification by reversible exchange for COVID-19 antiviral drug candidates
    H. Jeong, Sein Min, Heelim Chae · 2020 · Scientific Reports
36. The Impact of COVID-19 Pandemic on Seafood Safety and Human Health
    Nikheel Bhojraj Rathod, Nariman El Abed, Fatih Özoğul, Joe Mac Regenstein, Charis M. Galanakis, Sulaiman Omar Aljaloud, Salam Adnan Ibrahim · 2022 · Frontiers in Microbiology
37. Similarities and Differences between COVID-19-Associated Nephropathy and HIV-Associated Nephropathy
    Anqun Chen, Lijun Yin, Kyung Lee, Cijiang He · 2021 · Kidney Diseases
38. COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience
    Sanjiv Jasuja, Gaurav Sagar, Anupam Bahl, Shalini Verma · 2021 · International Journal of Nephrology
39. Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
    Musim Alotaibi, Ahmed Ali, Duaa M. Bakhshwin et al. · 2021 · International Journal of General Medicine
40. Acute Psychosis in COVID-19: Is It Due to Favipiravir Treatment or Acute Viral Illness?
    Murat Duyan, I. U. Ozturan · 2021 · SN Comprehensive Clinical Medicine
41. In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS‐CoV‐2
    T. Amparo, J. Seibert, T. C. Almeida · 2021 · Phytotherapy Research
42. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review
    Priyanka Dash, Subhashree Mohapatra, Sayantan Ghosh, Bismita Nayak · 2021 · Frontiers in Pharmacology
43. Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19
    Arghyadeep Bhattacharjee, Manish Saha, Arpita Halder, Arka Debnath, Oindrilla Mukherjee · 2021 · Current Microbiology
44. Therapeutic options for COVID-19: a quick review
    Muhammad Sani Ismaila, Faruku Bande, Aminu Ishaka, Aminatu Abubakar Sani, Karla C. Georges · 2021 · Journal of Chemotherapy
45. Recent progress in the repurposing of drugs/molecules for the management of COVID-19
    Divakar Sharma, Adinarayana Kunamneni · 2020 · Expert Review of Anti-infective Therapy
46. Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence with COVID-19 Infection: A Comprehensive Systematic Review and Meta-Analysis
    Hakan Akın, Ramazan Kurt, Fatih Tufan, Ahmed I. A. Swi, Reşat Özaras, Veysel Tahan, Ghassan M. Hammoud · 2020 · Diseases
47. The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19)
    Mojgan Sheikhpour · 2020 · Therapeutics and Clinical Risk Management
48. The efficacy and safety of antivirus drugs for COVID-19: A systematic review
    M. Munir, Hendra Kuganda, Amirah Basry · 2020
49. Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation
    Saleh A. Alqahtani, Abdulrahman Abdullah Aljumah, Almoutaz H. Hashim, Thamer H. Alenazi, Mohammed Aljawad, Waleed Al Hamoudi, Mohammed Y. Alghamdi · 2020 · Annals of Saudi Medicine
50. Repurposing of drugs for Covid-19: a systematic review and meta-analysis
    P. Kotecha, A. Light, E. Checcucci · 2020 · medRxiv
51. Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
    Md. Easin Mia, Mithu Howlader, Farzana Akter, Md. Murad Hossain · 2024 · Clinical Pathology
52. Determination of Favipiravir from Pharmaceutical Dosage Form by Extractive Ion Pair Complex Colorimetric Method
    R. V. Rele, Prathamesh P. Tiwatane · 2021 · Asian Journal of Research in Chemistry
53. Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19
    M. Bayram, O. Yildirim, R. S. Ozmen · 2021 · Cureus
54. Management of Coronavirus Disease 2019 (COVID‐19) Pandemic: From Diagnosis to Treatment Strategies
    Zhina Hadisi, Tavia Walsh, Seyed Mohammad Hossein Dabiri, Amir Seyfoori, David Hamdi, Bahram Mirani, Erik Pagan, Armando Jardim, Mohsen Akbari · 2020 · Advanced Therapeutics
55. Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19
    Xiaowei Gong, Shiwei Kang, Xianfeng Guo, Yan Li, Haixiang Gao, Yadong Yuan · 2021 · BMC Infectious Diseases
56. Evaluation of knowledge and attitudes among intensive care physicians during the COVID-19 pandemic: a cross-sectional survey
    Mesut Erbaş, Burhan Dost · 2020 · Sao Paulo Medical Journal
57. Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
    Shoya Iwanami, Keisuke Ejima, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka et al. · 2020 · medRxiv
58. Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review
    Ba’ Pham, Patricia de los Rios, Amruta Radhakrishnan, Nazia Darvesh, Jesmin Antony, Chantal Williams, Naveeta Ramkissoon, Gordon V. Cormack, Maura R. Grossman, Melissa Kampman et al. · 2022 · BMJ Open
59. Efficacy and safety of favipiravir plus interferon‐beta versus lopinavir/ritonavir plus interferon‐beta in moderately ill patients with COVID‐19: A randomized clinical trial
    Mehdi Hassaniazad, Hossein Farshidi, Abdollah Gharibzadeh · 2022 · Journal of Medical Virology
60. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia
    A. Mutair, Jinan Shamou, S. Alhumaid et al. · 2022 · Journal of Infection and Public Health
61. Efficacy of COVID-19 treatments among geriatric patients: a systematic review
    Helen Senderovich, Danusha Vinoraj, Madeline Stever, Sarah Waicus · 2022 · Therapeutic Advances in Infectious Disease
62. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study
    Zainab Almoosa, M. Saad, Samer Qara et al. · 2021 · Journal of Infection and Public Health
63. Scoping insight on antiviral drugs against COVID-19
    Ahmed S. Ali, Ibrahim M. Ibrahim, Abdulhadi S. Burzangi · 2021 · Arabian Journal of Chemistry
64. New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection
    Luana Vittoria Bauso, Chiara Imbesi, Irene Gasparo, G Calì, Alessandra Bitto · 2021 · Pharmaceuticals
65. COVID-19 Antiviral and Treatment Candidates: Current Status
    Erica Españo, Dajung Kim, Ji‐Yeon Kim, Song‐Kyu Park, Jeong-Ki Kim · 2021 · Immune Network
66. Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2
    Himani Rathi, Vishakha Burman, Sudip Kumar Datta, Satya Vati Rana, Anissa Atif Mirza, Sarama Saha, Raman Kumar, Manisha Naithani · 2021 · Indian Journal of Clinical Biochemistry
67. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases
    H. Takoi, Y. Togashi, D. Fujimori · 2020 · International Journal of Infectious Diseases
68. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges
    Xiaolei Yang, Ye Liu, Yuping Liu, Qing Yang, Xubo Wu, Xuan Huang, Huijia Liu, Weimin Cai, Guo Ma · 2020 · Expert Review of Clinical Pharmacology
69. A Narrative Review of Emerging Therapeutics for COVID-19
    Van C. Willis, Yull Edwin Arriaga, Dilhan Weeraratne, F. Leonardi Reyes, Gretchen Purcell Jackson · 2020 · Mayo Clinic Proceedings Innovations Quality & Outcomes
70. COVID-19 coronavirus: pathogenesis, clinical features, diagnostics, epidemiology, prevention and control
    Esmail M. El‐Fakharany, Yousra A. El‐Maradny, Abdelrahman M. Othman, Mina Gerges, Farah Belal, Ebthal Behery · 2020 · Microbial Biosystems
71. A Review of Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    F. Mohammadzadeh Rostami, Bahram Nasr Nasr Esfahani, A. Ahadi, Saman Shalibeik · 2020 · Iranian Journal of Medical Microbiology
72. COVID-19 signalome: Potential therapeutic interventions
    Kenneth H. Lundstrom, Altijana Hromić‐Jahjefendić, Esma Bilajac, Alaa A. A. Aljabali, Katarina Baralić, Nagwa A. Sabri, Eslam Mansour Shehata, Mohamed Raslan, Sara Ahmed Raslan, Ana Cláudia Barbosa Honório Ferreira et al. · 2022 · Cellular Signalling
73. Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats
    Sally Tarek Mahmoud, Marwa A. Moffid, Rawda M. Sayed, Eman A. Mostafa · 2022 · Microchemical Journal
74. Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trial
    S. M. Abdur Rahman, Ahmedul Kabir, Alend Abdullah, Md Billal Alam, Khan Abul Kalam Azad, Md Titu Miah, Syed Ghulam Mogni Mowla, Sudip Ranjan Deb, Mohammad Robed Amin, Muhammad Asaduzzaman · 2022 · Clinical Infection in Practice
75. Pharmacological repurposed agents for COVID-19
    Mohd Alaraj · 2022 · Research Journal of Pharmacy and Technology
76. Meta‐analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019
    Miao Yu, Deng‐Chao Wang, Sheng Li, Yue‐Hua Lei, Jian Wei, Li‐Yan Huang · 2021 · Journal of Medical Virology
77. The safety profile of favipiravir in COVID‐19 patients with severe renal impairment
    Selim Gök, Ömer Faruk Bahçecíoğlu, Mefküre Durmuş · 2021 · International journal of clinical practice
78. Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges
    Al Hakim, Md. Mahbub Hasan, Mahmudul Hasan, Syed Mohammad Lokman, Kazi Faizul Azim, Topu Raihan, Parveen Afroz Chowdhury, Abul Kalam Azad · 2021 · Frontiers in Microbiology
79. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach
    Mahmudul Hasan, Md Sorwer Alam Parvez, Kazi Faizul Azim, Md. Abdus Shukur Imran, Topu Raihan, Airin Gulshan, Samuel Muhit, Mst Rubaiat Nazneen Akhand, Syed Sayeem Uddin Ahmed, Md Bashir Uddin · 2021 · Biomedicine & Pharmacotherapy
80. Favipiravir Does Not Inhibit Chikungunya Virus Replication in Mosquito Cells and Aedes aegypti Mosquitoes
    Sofie Jacobs, Lanjiao Wang, A. R. Rosales Rosas · 2021 · Microorganisms
81. Favipiravir‐induced nephrotoxicity in a patient with COVID‐19: A case report
    Asmaa Abdelbary, Ahmad Eid Nazzal Alharafsheh, Afif Ahmed, Abdulqadir J. Nashwan · 2021 · Clinical Case Reports
82. Drugs intervention study in COVID-19 management
    Muhammad Taher, Noratika Tik, Deny Susanti Darnis · 2021 · Drug Metabolism and Personalized Therapy
83. Therapeutic Strategies in the Management of COVID-19
    Rajashri R. Naik, Ashok K. Shakya · 2021 · Frontiers in Molecular Biosciences
84. Umifenovir and coronavirus infections: a review of research results and clinical practice
    Irina A. Leneva, Natalia Yu. Pshenichnaya, Виля Ахтямовна Булгакова · 2020 · Terapevticheskii arkhiv
85. A pocket guide on how to structure SARS-CoV-2 drugs and therapies
    Dene R. Littler, Bruce J. MacLachlan, Gabrielle M. Watson, Julian P. Vivian, Benjamin S. Gully · 2020 · Biochemical Society Transactions
86. COVID‐19 in older adults: Retrospective cohort study in a tertiary hospital in Japan
    Tomoya Sano, Y. Kimizuka, Y. Fujikura et al. · 2020 · Geriatrics & Gerontology International
87. Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review
    Debjit Chakraborty, F. Debnath, S. Biswas · 2020 · Journal of Clinical Medicine Research
88. Pharmacotherapics Advice in Guidelines for COVID-19
    Zhang-Ren Chen, Ying Zhou, Jin Liu, Hongwei Peng, Jian Zhou, Haili Zhong, Lili Liu, Ming-Fang Lai, Xiaohua Wei, Jinhua Wen · 2020 · Frontiers in Pharmacology
89. How Does Arbidol Inhibit the Novel Coronavirus SARS-CoV-2? Atomistic Insights from Molecular Dynamics Simulations
    A. Padhi, Aniruddha Seal, Timir Tripathi · 2020
90. A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
    Saber Soltani, Amir Mohammad Zakeri, Mohammad Reza Karimi, Sara Akhavan Rezayat, Fatemeh Zomorodi Anbaji, Alireza Tabibzadeh, Parastoo Yousefi, Armin Zakeri, Ali Jafarpour, Mehdi Norouzi et al. · 2020 · Journal of Pharmaceutical Research International
91. Patogênese e perspectivas de tratamento da Covid-19: uma revisão
    Marcos Roberto Nascimento Sousa, Sabrina Sousa Barros, Marcelo Miranda da Silva, Ana Paula Melo Oliveira, Gabriel Mauriz de Moura Rocha, Guilherme Antônio Lopes de Oliveira · 2020 · Research Society and Development
92. The Importance of Glycosylation in COVID-19 Infection
    Tea Pribić, Gordan Lauc, Irena Trbojević‐Akmačić · 2021 · Advances in experimental medicine and biology
93. Age-dependent immune responses in COVID-19-mediated liver injury: focus on cytokines
    Nazanin Aghamohamadi, Faezeh Shahba, Ali Zarezadeh Mehrabadi, Hossein Khorramdelazad, Milad Karimi, Reza Falak, Reza Zolfaghari Emameh · 2023 · Frontiers in Endocrinology
94. Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects
    Özlem Akbal Dağıstan, Mustafa Sevım, S. Sen, Nur Sena Basarir, Meltem Culha, Aybige Erturk, Hanan Fael, Engin Kaptan, Serap Sancar, Lütfiye Mülazımoğlu et al. · 2022 · Pharmaceutics
95. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
    Prajakta Kulkarni, Sriram Padmanabhan · 2022 · Biotechnology Letters
96. Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial
    S. Joglekar, Shivakumar Iyer, Rohit Parate et al. · 2022 · Infectious Disease and Therapy
97. Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?
    Esther Y. Golnabi, James M. Sanders, Meagan L. Johns, Kevin Lin, Jessica K. Ortwine, Wenjing Wei, Norman S. Mang, James B Cutrell · 2021 · Current Infectious Disease Reports
98. Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral
    Xiao Jia, Ben Ganter, C. Meier · 2021 · Annual Reports in Medicinal Chemistry
99. A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease
    Muhammad Ikram Ullah, Yasir Ali, Muhammad Ramzan Khan · 2021 · Saudi Journal of Biological Sciences
100. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
     Mohammad Bosaeed, Ahmad M. Alharbi, Mohammad Hussein, Mohammed Abalkhail, Khizra Sultana, Abrar Musattat, Hajar AlQahtani, Majid M. Alshamrani, Ebrahim Mahmoud, Adel F Alothman et al. · 2021 · BMJ Open